Clonal evolution process from essential thrombocythemia to acute myeloid leukemia in the original patient from whom the CALR-mutated Marimo cell line was established Reviewed

Ushijima Y, Ishikawa Y, Nishiyama T, Kawashima N, Kanamori T, Sanada M, Kiyoi H

Nagoya Journal of Medical Science   Vol. 86 ( 2 ) page： 326 - 332   2024.5

急性骨髄性白血病に対する分子標的治療 Invited Reviewed

石川裕一

臨床血液   Vol. 64 ( 5 ) page： 345 - 354   2023.5

Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells Reviewed

    2022.3

Recent advances in molecular targeted therapy for acute myeloid leukemia Invited Reviewed

Yuichi Ishikawa

    2021.6

Clinical significance of MRD in AML Invited Reviewed

Yuichi Ishikawa

    2020.9

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults withFLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study Reviewed

Kawashima Naomi, Ishikawa Yuichi, Atsuta Yoshiko, Sawa Masashi, Ozawa Yukiyasu, Hayashi Masaki, Kohno Akio, Tomita Akihiro, Maeda Tomoya, Sakaida Emiko, Usuki Kensuke, Hagihara Maki, Kanamori Heiwa, Matsuoka Hiroshi, Kobayashi Miki, Asou Norio, Ohtake Shigeki, Matsumura Itaru, Miyazaki Yasushi, Naoe Tomoki, Kiyoi Hitoshi

CANCER SCIENCE   Vol. 111 ( 7 ) page： 2472 - 2481   2020.7

JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL) Reviewed

Fujita Hiroyuki, Ishikawa Yuichi, Yokoyama Yasuhisa

INTERNATIONAL JOURNAL OF HEMATOLOGY   Vol. 111 ( 6 ) page： 747 - 760   2020.6

FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development Reviewed

Kiyoi Hitoshi, Kawashima Naomi, Ishikawa Yuichi

CANCER SCIENCE   Vol. 111 ( 2 ) page： 312 - 322   2020.2

Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Reviewed

Ishikawa Y, Kawashima N, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H.

BLOOD ADVANCES     2020.1

Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Reviewed

Hidaka M, Inokuchi K, Uoshima N, Takahashi N, Yoshida N, Ota S, Nakamae H, Iwasaki H, Watanabe K, Kosaka Y, Komatsu N, Meguro K, Najima Y, Eto T, Kondo T, Kimura S, Yoshida C, Ishikawa Y, Sawa M, Hata T, Horibe K, Iida H, Shimomura T, Dobashi N, Sugiura I, Makiyama J, Miyagawa N, Sato A, Ito R, Matsumura I, Kanakura Y, Naoe T.

Japanese Journal of Clinical Oncology   Vol. 54 ( 2 ) page： 153 - 159   2024.2

Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. Reviewed

Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Kiyoi H.

American Journal of Hematology     2024.2

Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). Reviewed

Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Miyazaki Y, Kiyoi H.

International Journal of Hematology   Vol. 119 ( 2 ) page： 130 - 145   2023.12

Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation Reviewed

Ito M, Fukushima N, Fujii T, Numata M, Morikawa S, Kawamura Y, Goto M, Kohno A, Imahashi N, Yasuda T, Sanada M, Ishikawa Y, Kiyoi H, Ozeki K.

International Journal of Hematology   Vol. 119 ( 1 ) page： 80 - 87   2023.11

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11). Reviewed

Usuki K, Ohtake S, Honda S, Matsuda M, Wakita A, Nawa Y, Takase K, Maeda A, Sezaki N, Yokoyama H, Takada S, Hirano D, Tomikawa T, Sumi M, Yano S, Handa H, Ota S, Fujita H, Fujimaki K, Mugitani A, Kojima K, Kajiguchi T, Fujimoto K, Asou N, Usui N, Ishikawa Y, Katsumi A, Matsumura I, Kiyoi H, Miyazaki Y.

International Journal of Hematology   Vol. 119 ( 1 ) page： 24 - 38   2023.11

Targeting cis-regulatory elements of FOXO family is a novel therapeutic strategy for induction of leukemia cell differentiation. Reviewed

Kurayoshi K, Takase Y, Ueno M, Ohta K, Fuse K, Ikeda S, Watanabe T, Nishida Y, Horike SI, Hosomichi K, Ishikawa Y, Tadokoro Y, Kobayashi M, Kasahara A, Jing Y, Shoulkamy MI, Meguro-Horike M, Kojima K, Kiyoi H, Sugiyama H, Nagase H, Tajima A, Hirao A.

Cell Death & Disease   Vol. 14 ( 9 ) page： 642   2023.9

High-risk Combinations of Additional Chromosomal Abnormalities in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: JALSG Ph+ALL TKI-SCT Study. Reviewed

Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Taniguchi Y, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Kiyoi H, Matsumura I, Miyazaki Y.

Hemasphere   Vol. 7 ( 6 ) page： e989   2023.6

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide Reviewed

Naoe T, Saito A, Hosono N, Kasahara S, Muto H, Hatano K, Ogura M, Masunari T, Tanaka M, Usuki K, Ishikawa Y, Ando K, Kondo Y, Takagi Y, Takada S, Ishikawa M, Choi I, Sano A, Nagai H.

Cancer Immunology, Immunotherapy   Vol. 72 ( 8 ) page： 2865 - 2871   2023.4

Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy Reviewed

Yoshida C, Kondo T, Ito T, Kizaki M, Yamamoto K, Miyamoto T, Morita Y, Eto T, Katsuoka Y, Takezako N, Uoshima N, Imada K, Ando J, Komeno T, Mori A, Ishikawa Y, Satake A, Watanabe J, Kawakami Y, Morita T, Taneike I, Nakayama M, Duan Y, Garbayo Guijarro B, Delgado A, Llamas C, Kiyoi H.

NTERNATIONAL JOURNAL OF HEMATOLOGY   Vol. 116 ( 8 ) page： 89 - 101   2022.8

急性骨髄性白血病の初期診断と外来治療 Invited

石川裕一

日本内科学会雑誌   Vol. 111 ( 7 )   2022.7

Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia Reviewed

3. Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, Tanaka M, Kako S, Matsuda M, Yokoyama H, Ishikawa Y, Taniguchi Y, Hagihara M, Ozawa Y, Ueda Y, Hirano D, Sakura T, Tsuji M, Kamae T, Fujita H, Hiramoto N, Onoda M, Fujisawa S, Hatta Y, Dobashi N, Nishiwaki S, Atsuta Y, Kobayashi Y, Hayakawa F, Ohtake S, Naoe T, Miyazaki Y.

BLOOD ADVANCES   Vol. 6 ( 2 ) page： 624 - 636   2022.1

Follicular T-cell lymphoma mimicking lymphocyte-rich classic Hodgkin lymphoma: a case report of a diagnostic pitfall. Reviewed

Sakakibara A, Suzuki Y, Kato H, Yamamoto K, Sakata-Yanagimoto M, Ishikawa Y, Furukawa K, Shimada K, Kohno K, Nakamura S, Satou A, Kato S.

Journal of Clinical and Experimental Hematopathology     2021.6

Unusual presentation of recurrent follicular lymphoma as diffuse granular shadow. Reviewed

Ito T, Okachi S, Ishikawa Y, Shimada S, Wakahara K, Hashimoto N.

Respirology case reports     2021.2

Machine learning-aided risk stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia. Reviewed

BIOMARKER RESEARCH   Vol. 9 ( 1 ) page： 13   2021.2

Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation

Goto Tatsunori, Murata Makoto, Nishida Tetsuya, Terakura Seitaro, Kamoshita Sonoko, Ishikawa Yuichi, Ushijima Yoko, Adachi Yoshiya, Suzuki Satoshi, Kato Katsuyoshi, Hirakawa Akihiro, Nishiwaki Satoshi, Nishio Nobuhiro, Takahashi Yoshiyuki, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi

STEM CELLS TRANSLATIONAL MEDICINE     2020.12

Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features Reviewed

Nishiwaki Satoshi, Kim Jeong Hui, Ito Masafumi, Maeda Matsuyoshi, Okuno Yusuke, Koyama Daisuke, Ozawa Yukiyasu, Gunji Masaharu, Osaki Masahide, Kitamura Kunio, Ushijima Yoko, Ishikawa Yuichi, Miyamura Koichi, Sugiura Isamu, Kiyoi Hitoshi

FRONTIERS IN ONCOLOGY   Vol. 10   2020.10

Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study. Reviewed

Yasuda T, Sanada M, Nishijima D, Kanamori T, Iijima Y, Hattori H, Saito A, Miyoshi H, Ishikawa Y, Asou N, Usuki K, Hirabayashi S, Kato M, Ri M, Handa H, Ishida T, Shibayama H, Abe M, Iriyama C, Karube K, Nishikori M, Ohshima K, Kataoka K, Yoshida K, Shiraishi Y, Goto H, Adachi S, Kobayashi R, Kiyoi H, Miyazaki Y, Ogawa S, Kurahashi H, Yokoyama H, Manabe A, Iida S, Tomita A, Horibe K

CANCER SCIENCE     2020

New TARGET investigators. Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line Reviewed

Sakurai M, Okamoto S, Matsumura I, Murakami S, Takizawa M, Waki M, Hirano D, Watanabe-Nakaseko R, Kobayashi N, Iino M, Mitsui H, Ishikawa Y, Takahashi N, Kawaguchi T, Suzuki R, Yamamoto K, Kizaki M, Ohnishi K, Naoe T, Akashi K

INTERNATIONAL JOURNAL OF HEMATOLOGY   Vol. 111   page： 812 - 825   2020

Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells

Goto Tatsunori, Murata Makoto, Nishida Tetsuya, Terakura Seitaro, Kamoshita Sonoko, Ishikawa Yuichi, Ushijima Yoko, Adachi Yoshiya, Kato Katsuyoshi, Hirakawa Akihiro, Nishiwaki Satoshi, Nishio Nobuhiro, Takahashi Yoshiyuki, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi

BLOOD   Vol. 134   2019.11

Development of Predictive Biomarker and Optimal Treatment Strategy with FLT3 Inhibitors in Acute Myeloid Leukemia

Kim Jeong Hui, Harada Yasuhiko, Ishikawa Yuichi, Kawashima Naomi, Nakashima Marie, Ushijima Yoko, Nishiyama Takahiro, Goto Tatsunori, Fukushima Nobuaki, Kihara Rika, Kajiguchi Tomohiro, Watamoto Koichi, Kohno Akio, Kitamura Kunio, Ozawa Yukiyasu, Kiyoi Hitoshi

BLOOD   Vol. 134   2019.11

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens

Ishikawa Yuichi, Saito Koichi, Kawashima Naomi, Morimoto Michie, Murao Hidetoshi, Terada Daisuke, Yamaura Takeshi, Hagiwara Shinji, Kiyoi Hitoshi

BLOOD   Vol. 134   2019.11

Dynamics of Genetic Landscapes and Clonal Evolution between Patients and PDX Models in Acute Myeloid Leukemia

Kawashima Naomi, Ishikawa Yuichi, Akashi Akimi, Hattori Hikaru, Yamaguchi Yohei, Nishiyama Takahiro, Kihara Rika, Ozawa Yukiyasu, Kiyoi Hitoshi

BLOOD   Vol. 132   2018.11

Anti-Leukemic Effect of Retinoic Acid in Non-APL AML Cells

Harada Yasuhiko, Ishikawa Yuichi, Kawashima Naomi, Hattori Hikaru, Yamaguchi Yohei, Adachi Yoshiya, Ushijima Yoko, Kiyoi Hitoshi

BLOOD   Vol. 132   2018.11

Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia Reviewed

Hattori Hikaru, Ishikawa Yuichi, Kawashima Naomi, Akashi Akimi, Yamaguchi Yohei, Harada Yasuhiko, Hirano Daiki, Adachi Yoshiya, Miyao Kotaro, Ushijima Yoko, Terakura Seitaro, Nishida Tetsuya, Matsushita Tadashi, Kiyoi Hitoshi

PLOS ONE   Vol. 13 ( 10 ) page： e0204850   2018.10

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study. Reviewed

Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H, Japan Adult Leukemia Study Group (JALSG).

Annals of hematology     2018.9

Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: A clinical study protocol

Goto Tatsunori, Murata Makoto, Terakura Seitaro, Nishida Tetsuya, Adachi Yoshiya, Ushijima Yoko, Shimada Kazuyuki, Ishikawa Yuichi, Hayakawa Fumihiko, Nishio Nobuhiro, Nishiwaki Satoshi, Hirakawa Akihiro, Kato Katsuyoshi, Takahashi Yoshiyuki, Kiyoi Hitoshi

MEDICINE   Vol. 97 ( 17 ) page： e0449   2018.4

Mutation analysis of therapy-related myeloid neoplasms Reviewed

Nishiyama Takahiro, Ishikawa Yuichi, Kawashima Naomi, Akashi Akimi, Adachi Yoshiya, Hattori Hikaru, Ushijima Yoko, Kiyoi Hitoshi

CANCER GENETICS   Vol. 222   page： 38 - 45   2018.4

Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS.

Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, Al-Raqad M, Maeda M, Schoonenberg VAC, Cole MA, Macias-Trevino C, Ishikawa Y, Yao Q, Nakano M, Arai F, Orkin SH, Reversade B, Buonamici S, Pinello L, Akashi K, Bauer DE, Maeda T

Cancer cell   Vol. 33 ( 3 ) page： 386-400.e5   2018.3

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study Reviewed

Harada Yasuhiko, Nagata Yasunobu, Kihara Rika, Ishikawa Yuichi, Asou Norio, Ohtake Shigeki, Miyawaki Shuichi, Sakura Toru, Ozawa Yukiyasu, Usui Noriko, Kanamori Heiwa, Ito Yoshikazu, Imai Kiyotoshi, Suehiro Youko, Kobayashi Shinichi, Kitamura Kunio, Sakaida Emiko, Onizuka Makoto, Takeshita Akihiro, Ishida Fumihiro, Suzushima Hitoshi, Ishizawa Kenichi, Naoe Tomoki, Matsumura Itaru, Miyazaki Yasushi, Ogawa Seishi, Kiyoi Hitoshi

LEUKEMIA RESEARCH   Vol. 66   page： 20-27   2018.3

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations

Yamaura Takeshi, Nakatani Toshiyuki, Uda Ken, Ogura Hayato, Shin Wigyon, Kurokawa Naoya, Saito Koichi, Fujikawa Norie, Date Tomomi, Takasaki Masaru, Terada Daisuke, Hirai Atsushi, Akashi Akimi, Chen Fangli, Adachi Yoshiya, Ishikawa Yuichi, Hayakawa Fumihiko, Hagiwara Shinji, Naoe Tomoki, Kiyoi Hitoshi

BLOOD   Vol. 131 ( 4 ) page： 426 - 438   2018.1

Intrabone single unit cord blood transplantation for hematological malignancies

Murata Makoto, Maeda Yoshinobu, Masuko Masayoshi, Fukuhara Noriko, Nishida Tetsuya, Terakura Seitaro, Ishikawa Yuichi, Tanimoto Mitsune, Shibasaki Yasuhiko, Suzuki Ritsuro, Kodera Yoshihisa, Kiyoi Hitoshi, Naoe Tomoki

CANCER SCIENCE   Vol. 109   page： 757-757   2018.1

[MonoMAC syndrome patient developing myelodysplastic syndrome following persistent EBV infection].

Yamamoto H, Hattori H, Takagi E, Morishita T, Ishikawa Y, Terakura S, Nishida T, Ito Y, Murata M, Kiyoi H

[Rinsho ketsueki] The Japanese journal of clinical hematology   Vol. 59 ( 3 ) page： 315-322   2018

Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia Invited Reviewed

  Vol. 59 ( 10 ) page： 1997-2006   2018

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia

Adachi Yoshiya, Ishikawa Yuichi, Kiyoi Hitoshi

ONCOTARGET   Vol. 8 ( 45 ) page： 78452 - 78465   2017.10

Abscopal Effect of Local Irradiation Treatment for Diffuse Large B-cell Lymphoma

Hidaka Yuri, Takeichi Takuya, Ishikawa Yuichi, Kawamura Mariko, Akiyama Masashi

ACTA DERMATO-VENEREOLOGICA   Vol. 97 ( 9 ) page： 1140-1141   2017.10

Core-binding factor白血病における遺伝子異常 Invited Reviewed

石川裕一

臨床血液   Vol. 58 ( 8 ) page： 991-998   2017.9

Phase II study of intrabone single unit cord blood transplantation for hematological malignancies

Murata Makoto, Maeda Yoshinobu, Masuko Masayoshi, Onishi Yasushi, Endo Tomoyuki, Terakura Seitaro, Ishikawa Yuichi, Iriyama Chisako, Ushijima Yoko, Goto Tatsunori, Fujii Nobuharu, Tanimoto Mitsune, Kobayashi Hironori, Shibasaki Yasuhiko, Fukuhara Noriko, Inamoto Yoshihiro, Suzuki Ritsuro, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi, Naoe Tomoki, Nishida Tetsuya

CANCER SCIENCE   Vol. 108 ( 8 ) page： 1634 - 1639   2017.8

Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia Reviewed

  Vol. 8 ( 45 ) page： 78452-78465   2017.7

Malignant lymphoma with cardiac involvement.

Terakura S, Onji M, Iriyama C, Goto T, Ushijima Y, Shimada K, Ishikawa Y, Nishida T, Hayakawa F, Murata M, Kiyoi H

  Vol. 58 ( 3 ) page： 239-242   2017

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells Reviewed

Fangli Chen, Yuichi Ishikawa, Akimi Akashi, Tomoki Naoe and Hitoshi Kiyoi

  Vol. 7 ( 30 ) page： 47018-32   2016.7

Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology Reviewed

Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T

Haematologica   Vol. 100 ( 4 ) page： 439-51   2015.4

Snx3 Regulates Recycling of the Transferrin Receptor and Iron Assimilation Reviewed

Chen C, Garcia-Santos D, Ishikawa Y, Seguin A, Li L, Fegan KH, Hildick-Smith GJ, Shah DI, Cooney JD, Chen W, King MJ, Yien YY, Schultz IJ, Anderson H, Dalton AJ, Freedman ML, Kingsley PD, Palis J, Hattangadi SM, Lodish HF, Ward DM, Kaplan J, Maeda T, Ponka P, Paw BH

Cell Metab.   Vol. 17 ( 3 ) page： 343-52   2013.3

LRF-mediated Dll4 repression in erythroblasts is necessary for hematopoietic stem cell maintenance Reviewed

Lee SU, Maeda M, Ishikawa Y, Li SM, Wilson A, Jubb AM, Sakurai N, Weng L, Fiorini E, Radtke F, Yan M, Macdonald HR, Chen CC, Maeda T

Blood.   Vol. 121 ( 6 ) page： 918-929   2013.2

GATA2 zinc finger 2 mutation found in acute myeloid leukemia impairs myeloid differentiation. Reviewed

Niimi K, Kiyoi H, Ishikawa Y, Hayakawa F, Kurahashi S, Kihara R, Tomita A, Naoe T

Leukemia research reports   Vol. 2 ( 1 ) page： 21-5   2013

The LRF transcription factor regulates mature B cell development and the germinal center response in mice Reviewed

Sakurai N, Maeda M, Lee SU, Ishikawa Y, Li M, Williams JC, Wang L, Su L, Suzuki M, Saito TI, Chiba S, Casola S, Yagita H, Teruya-Feldstein J, Tsuzuki S, Bhatia R, Maeda T

J Clin Invest.   Vol. 121 ( 7 ) page： 2583-98   2011.7

Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia Reviewed

Ishikawa Y, Kiyoi H, Naoe T

Leuk Res.   Vol. 35 ( 5 ) page： 685-8   2011.5

A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis Reviewed

Sakai K, Ishikawa Y, Mori Y, Kobayashi M, Iriyama C, Ozawa Y, Suzuki T, Minami Y, Ishikawa K, Kaneda N, Naoe T, Kiyoi H

Int J Hematol.   Vol. 93 ( 2 ) page： 237-42   2011.2

Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia. Reviewed

Tsujimura A, Kiyoi H, Shiotsu Y, Ishikawa Y, Mori Y, Ishida H, Toki T, Ito E, Naoe T

International journal of hematology   Vol. 92 ( 4 ) page： 624-33   2010.11

Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study Reviewed

Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K, Kohno A, Sugiura I, Yokozawa T, Hanamura A, Yamamoto K, Iida H, Emi N, Suzuki R, Ohnishi K, Naoe T

Cancer Sci.   Vol. 101 ( 10 ) page： 2186-92   2010.10

Array-based genomic resequencing of human leukemia. Reviewed

Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL, Ueno T, Soda M, Hamada T, Haruta H, Takada S, Miyazaki Y, Kiyoi H, Ito E, Naoe T, Tomonaga M, Toyota M, Tajima S, Iwama A, Mano H

Oncogene   Vol. 29 ( 25 ) page： 3723-31   2010.6

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation Reviewed

Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H, Ishii K, Mori Y, Ozeki K, Minami Y, Abe A, Maeda H, Akiyama T, Kanda Y, Sato Y, Akinaga S, Naoe T

Blood.   Vol. 114 ( 8 ) page： 1607-17   2009.8

Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia Reviewed

Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, Kuriyama K, Tomonaga M, Naoe T

Eur J Haematol.   Vol. 83 ( 2 ) page： 90-98   2009.8

Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes Reviewed

Ishikawa Y, Xu J, Sakashita G, Urano T, Suzuki T, Tomita A, Kiyoi H, Nakamura S, Naoe T

Leuk Lymphoma. 49   Vol. 49 ( 12 ) page： 2359-64   2009.8

WHO分類に基づく急性骨髄性白血病における網羅的遺伝子変異の解析 Invited Reviewed

石川裕一

臨床血液   Vol. 50 ( 8 ) page： 597-603   2009

Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. Reviewed

Iwasaki T, Katsumi A, Kiyoi H, Tanizaki R, Ishikawa Y, Ozeki K, Kobayashi M, Abe A, Matsushita T, Watanabe T, Amano M, Kojima T, Kaibuchi K, Naoe T

European journal of haematology   Vol. 81 ( 6 ) page： 454-60   2008.12

Mutational analysis of SOS1 gene in acute myeloid leukemia. Reviewed

Tanizaki R, Katsumi A, Kiyoi H, Kunishima S, Iwasaki T, Ishikawa Y, Kobayashi M, Abe A, Matsushita T, Watanabe T, Kojima T, Kaibuchi K, Kojima S, Naoe T

International journal of hematology   Vol. 88 ( 4 ) page： 460-2   2008.11

癌と化学療法　「急性骨髄性白血病に対する分子標的薬　FLT3阻害剤の現状と課題」

石川裕一（ Role： Joint author）

癌と化学療法社  2022.5 

血液内科「再発・難治性AMLに対する治療戦略」

石川　裕一

科学評論社  2021.8 

血液内科「CBF関連転座を有する急性骨髄性白血病の予後と治療」

石川　裕一

科学評論社  2020.4 

EBM　血液疾患の治療　2021-2022

石川裕一、清井仁（ Role： Contributor ,  骨髄系腫瘍に対するクリニカルシーケンス）

中外医学社  2020 

白血病治療マニュアル改訂第4版

石川裕一（ Role： Contributor ,  fit初発例の治療プロトコール）

南江堂  2020 

日本臨床　造血器腫瘍学

石川裕一、清井仁（ Role： Contributor ,  分子標的療法(TKI, エピジェネティック修飾, PI, IMIDs含む)）

日本臨床社  2020 

急性白血病診療テキスト

石川裕一（ Role： Contributor ,  急性骨髄性白血病　染色体・遺伝子異常）

中外医学社  2020 

内科「白血病の治療　急性骨髄性白血病」

石川　裕一

南江堂  2019.10 

臨床検査「急性リンパ芽球性白血病(前駆リンパ球性腫瘍)の遺伝子異常」

石川　裕一

医学書院  2019.7 

血液疾患　最新の治療　2020-2022

石川裕一（ Role： Contributor ,  急性骨髄性白血病）

南江堂  2019 

WHO血液腫瘍分類　WHO分類2017をうまく活用するために　「NPM1遺伝子変異を伴う急性骨髄性白血病」 「両アレルのCEBPA遺伝子変異を伴う急性骨髄性白血病」

石川裕一（ Role： Sole author）

医薬ジャーナル社  2018.10 

血液内科「成人急性骨髄性白血病における遺伝子変異による微小残存病変の検出とその意義」

石川裕一, 清井仁（ Role： Joint author）

科学評論社  2018.5 

メディカル・サイエンス・ダイジェスト　「急性骨髄性白血病の病態解明と分子標的治療」

石川　裕一（ Role： Sole author）

ニューサイエンス社  2017.7 

日本臨床 白血病学（上）「遺伝子突然変異による骨髄性腫瘍の発症機序：概論」

石川　裕一、清井　仁（ Role： Joint author）

日本臨牀社  2016.10 

造血器腫瘍アトラス　改訂第5版　「急性白血病の遺伝子異常」

石川　裕一, 清井　仁（ Role： Joint author）

日本医事新報社  2016.7 

Annual Review 血液 2016　「異常転写因子(CBFβ-SMMHC)を標的とした急性骨髄性白血病に対する新規治療薬の開発」

石川裕一、清井仁（ Role： Joint author）

中外医学社  2016.1 

腫瘍内科 「AMLの予後解析 -Simpson's paradox-」

石川裕一、清井仁（ Role： Joint author）

科学評論社  2015.12 

血液疾患　診断・治療指針　「急性骨髄性白血病 (non-APL)」

石川　裕一, 清井　仁（ Role： Joint author）

中山書店  2015.10 

血液内科　「AML/MDSに対する新規低分子化合物の現状と展望」

石川裕一、清井仁（ Role： Joint author）

科学評論社  2015.2 

Annual Review 血液 2015　「急性骨髄性白血病のゲノム解析」

石川裕一、清井仁（ Role： Sole author）

中外医学社  2015.1 

血液フロンティア　「急性白血病のクローン性」

石川裕一、清井仁（ Role： Joint author）

医薬ジャーナル社  2014.6 

急性骨髄性白血病におけるMRDの意義 Invited

石川裕一

第82回日本血液学会学術集会  2020.10  日本血液学会

FF-10101 Retains Potent Inhibitory Activities Against Resistant Mutations to FLT3 Inhibitors, Newly Identified in Random Mutagenesis Screens International conference

Y Ishikawa, K Saito, N Kawashima, M Morimoto, H Murao, D Terada, T Yamaura, S Hagiwara, H Kiyoi

61th American Society of Hematology Annual Meeting and Exposition  2019.12 

CBF-AMLの分子病態と治療 Invited

石川裕一

第80回日本血液学会学術集会 

Interim analysis of the New TARGET Observational Study 1, a prospective observational study for newly diagnosed CML in Japan

Yuichi Ishikawa, Hitoshi Kiyoi, Ritsuro Suzuki, Tatsuya Kawaguchi, Naoto Takahashi, Kazuhito Yamamoto, Kazunori Ohnishi, Masahiro Kizaki, Tomoki Naoe, Itaru Matsumura

Recent progress and problems in FLT3 inhibitor development Invited

Y Ishikawa

The Japan Adult Leukemia Study Group 30th Anniversary International Symposium 

Cooperative mutations in core-binding factor-AML Invited International conference

Y Ishikawa

The 19th Korean Society of Hematology AML/MDS Working Party Symposium 

Cooperative mutations in AML with recurrent genetic abnormalities Invited

Cellular mechanisms for transferrin receptor endocytosis vital for terminal erythroid differentiation International conference

Y Ishikawa, S. K. Tacheva-Grigorova, M Maeda, F Aguet, S Lee, M Ericsson, A Mullally, T Kirchhausen and T Maeda

Cellular mechanisms for transferrin receptor endocytosis vital for terminal erythroid differentiation International conference

Y Ishikawa, S. K. Tacheva-Grigorova, M Maeda, F Aguet, S Lee, M Ericsson, T Kirchhausen and T Maeda

55th American Society of Hematology Annual Meeting and Exposition 

Clathrin Assembly Protein CALM is Necessary for Leukemia cell Proliferation and Erythroid Development via Regulating Transferrin Receptor Endocytosis International conference

Y Ishikawa, M Maeda, M Li, S Lee, J Feldstein, H Kiyoi, T Naoe, M Weiss, J Heuser and T Maeda

53th American Society of Hematology Annual Meeting and Exposition 

Clathrin assembly protein CALM plays a key role in erythroid differentiation via regulating transferrin receptor endocytosis International conference

Y Ishikawa, M Maeda, M Li, S Lee, JE Heuser and T Maeda

52th American Society of Hematology Annual Meeting and Exposition 

急性骨髄性白血病(AML)の発症・進展に関与するエンドサイトーシス機能異常と、それを標的とする治療法の開発

2014.10 - 2016.3

グラクソ・スミスクライン研究助成 

Case study -血液疾患-　貧血の鑑別と治療

2022

血液病「骨髄増殖性腫瘍」

2021